Roddy Gavin W

Roddy Gavin W, Kohli Darrell, Niknam Parvin, Omer Mohammed E, Chowdhury Uttio Roy, Anderson Kjersten J et al.

Subconjunctival gene therapy (AAV-STC-1) significantly lowered intraocular pressure in mice for weeks, offering a potential sustained glaucoma treatment with fewer side effects than daily drops.

Kaplan Tyler M, Sit Arthur J, Patel Sanjay V, Roddy Gavin W

Four LASIK patients developed progressive paracentral visual field loss at low IOPs (≤12 mmHg), requiring single-digit targets. This suggests LASIK may increase glaucoma risk, possibly via reduced corneal hysteresis, necessitating lower IOP goals.

Liu Alice S, Lyons Lance J, Khanna Cheryl L, Roddy Gavin W, Hodge David O, Sit Arthur J

Increased laser energy caused more damage to single-use SLT lenses, which correlated with diminished treatment effectiveness. This suggests reconsidering their routine use.

Kaplan Tyler M, Hammer Jon D, Kohli Darrel, Pacheco Johann M, Hodge David O, Khanna Cheryl L et al.

SLT efficacy was studied in immunosuppressed patients. Early IOP reduction was similar, but at one year, immunosuppressed patients had a diminished treatment response, suggesting less sustained benefit.

Roddy Gavin W

Roddy Gavin W, Sit Arthur J

Advancing Tenon's layer during trabeculectomy improved bleb morphology, creating diffuse, low-lying, non-ischemic blebs. This modification may enhance surgical success and reduce complications.

Roy Chowdhury Uttio, Millar J Cameron, Holman Bradley H, Anderson Kjersten J, Dosa Peter I, Roddy Gavin W et al.

ATP-sensitive potassium channel openers (CKLP1, diazoxide) effectively lowered intraocular pressure in ocular hypertensive mouse models by decreasing episcleral venous pressure, suggesting a new glaucoma treatment approach.

Funk Robert O, Hodge David O, Kohli Darrell, Roddy Gavin W

This study found multiple systemic vascular conditions (e.g., hypertension, diabetes, migraine) are linked to low-tension glaucoma, strengthening evidence for a vascular component in its development and guiding patient evaluation.

Wu Kristi Y, Hodge David O, White Launia J, McDonald Jacinta, Roddy Gavin W

Metabolic syndrome was linked to higher intraocular pressure and ocular hypertension, but this association was largely explained by thicker corneas, suggesting corneal thickness as a key factor.

Kilgore Khin P, Wang Feng, Stern Nicole C, Sabbagh Nouran, Jamali Sepideh, White Launia J et al.

This study found Ahmed FP7 and Baerveldt 350 glaucoma drainage devices significantly increase diplopia risk (~20%) compared to Baerveldt 250 or controls (~5%). This risk should be discussed preoperatively.

Roddy Gavin W

Metabolic syndrome accelerates retinal neuron aging via metabolic stress, potentially contributing to glaucoma and AMD, highlighting its clinical relevance as a modifiable risk factor.

Farazdaghi Marybeth K, Lyons Lance J, Roddy Gavin W

This case reports recurrent, delayed hyphema after iStent Inject, successfully managed by device removal. It suggests hyphema resulted from blood reflux into the anterior chamber via collector channels when IOP dropped, highlighting a potential complication and its treatment.

Roddy Gavin W

This review found Metabolic Syndrome is linked to ocular hypertension and glaucoma. This suggests managing MetS could potentially impact glaucoma risk and progression.

Roddy Gavin W, Zhao Bingying, Wang Feng, Fang Chengbo, Khanna Sunil S, Bajric Jasmina et al.

Glaucoma surgery, particularly drainage devices, significantly increases postoperative ptosis risk compared to cataract surgery. This warrants patient counseling and potential oculoplastic referral.

Roddy Gavin W, Brodsky Michael C, Chen John J

Roddy Gavin W, Viker Kimberly B, Winkler Nelson S, Bahler Cindy K, Holman Bradley H, Sheikh-Hamad David et al.

Latanoprost lowers eye pressure by increasing Stanniocalcin-1 (STC-1). STC-1 itself also reduces intraocular pressure, suggesting it's a key mediator and potential new glaucoma therapy.